PE20170148A1 - Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer - Google Patents
Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancerInfo
- Publication number
- PE20170148A1 PE20170148A1 PE2016002393A PE2016002393A PE20170148A1 PE 20170148 A1 PE20170148 A1 PE 20170148A1 PE 2016002393 A PE2016002393 A PE 2016002393A PE 2016002393 A PE2016002393 A PE 2016002393A PE 20170148 A1 PE20170148 A1 PE 20170148A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- methoxy
- cancer
- treatment
- triazin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- -1 1,2,4-triazin-3-yl Chemical group 0.000 abstract 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 abstract 4
- 101710184006 Glutaminase 1 Proteins 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se refiere a un compuesto de formula I, donde: Q es piridazin-3-ilo; 1,2,4-triazin-3-ilo o 1,2,4-triazin-6-ilo; R es hidroxilo, fluor o metoxi; R1 es hidroxilo, metoxi, difluorometoxi o trifluorometoxi; R2 es metilo o etilo. Son compuestos preferidos: (2S)-2-metoxi-2-fenil-N-[5-[[(3R)-1-(1,2,4-triazin-3-il)pirrolidin-3-il]amino]-1,3-4-tiadiazol-2-il]acetamida; (2S)-2-metoxi-2-fenil-N-[5-[[(3R)-1-piridazin-3-ilpirrolidin-3-il]amino]-1,3-4-tiadiazol-2-il]acetamida; entre otros. Tambien se refiere a una composicion farmaceutica. Dichos compuestos son inhibidores de la enzima glutaminasa 1 (GLS1), siendo utiles en el tratamiento del cancer
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1409624.2A GB201409624D0 (en) | 2014-05-30 | 2014-05-30 | 1,3,4-thiadiazole compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170148A1 true PE20170148A1 (es) | 2017-04-05 |
Family
ID=51214473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016002393A PE20170148A1 (es) | 2014-05-30 | 2015-05-27 | Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer |
Country Status (40)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201520959D0 (en) | 2015-11-27 | 2016-01-13 | Astrazeneca Ab And Cancer Res Technology Ltd | Bis-pyridazine compounds and their use in treating cancer |
| US9938265B2 (en) * | 2015-11-30 | 2018-04-10 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| US10040789B2 (en) * | 2015-11-30 | 2018-08-07 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| US10323028B2 (en) * | 2015-11-30 | 2019-06-18 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| CN110741003B (zh) * | 2017-06-13 | 2021-07-23 | 南京明德新药研发有限公司 | 作为gls1抑制剂的化合物 |
| JP2019064976A (ja) * | 2017-10-03 | 2019-04-25 | 国立大学法人 熊本大学 | 抗がん剤 |
| ES2939506T3 (es) * | 2018-10-16 | 2023-04-24 | Medshine Discovery Inc | Derivado de tiadiazol y usos del mismo como inhibidor de GLS1 para el tratamiento de cáncer |
| MA55198A (fr) * | 2019-03-05 | 2022-01-12 | Astrazeneca Ab | Composés tricycliques fusionnés utiles en tant qu'agents anticancéreux |
| WO2024233839A1 (en) * | 2023-05-10 | 2024-11-14 | Leal Therapeutics, Inc. | Small molecule inhibitors of glutaminase |
| CN116854582B (zh) * | 2023-07-10 | 2025-08-29 | 泰州葛林美克医药科技有限公司 | 一种对映纯α-甲氧基苯乙酸的制备方法 |
| CN117003745B (zh) * | 2023-07-20 | 2024-06-07 | 南京市第一医院 | Gls1/hdac双靶点抑制剂及其合成方法和应用 |
| WO2025196446A1 (en) | 2024-03-22 | 2025-09-25 | Sitryx Therapeutics Limited | Thiadiazoles as glutaminase 1 inhibitors |
| WO2025196447A1 (en) | 2024-03-22 | 2025-09-25 | Sitryx Therapeutics Limited | Thiadiazoles as glutaminase 1 inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003288956A1 (en) * | 2002-10-30 | 2004-06-07 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| US20140186325A1 (en) | 2011-06-10 | 2014-07-03 | President And Fellows Of Harvard College | Methods of Cancer Treatment and Prevention Through the Modulation of SIRT4 Activity |
| HRP20192144T1 (hr) * | 2011-11-21 | 2020-02-21 | Calithera Biosciences Inc. | Heterociklični inhibitori glutaminaze |
| WO2014043633A1 (en) * | 2012-09-17 | 2014-03-20 | Agios Pharmaceuticals, Inc. | Use of e-cadherin and vimentin for selection of treatment responsive patients |
| LT2920168T (lt) | 2012-11-16 | 2021-10-25 | Calithera Biosciences, Inc. | Heterociklinis gliutaminazės inhibitorius |
| CN105263915B (zh) | 2012-11-21 | 2019-04-12 | 安吉奥斯医药品有限公司 | 谷氨酰胺酶抑制剂及使用方法 |
| WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| US9029531B2 (en) * | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
| AU2013356241A1 (en) | 2012-12-03 | 2015-07-09 | Calithera Biosciences, Inc. | Treatment of cancer with heterocyclic inhibitors of glutaminase |
-
2014
- 2014-05-30 GB GBGB1409624.2A patent/GB201409624D0/en not_active Ceased
-
2015
- 2015-05-27 PE PE2016002393A patent/PE20170148A1/es unknown
- 2015-05-27 MY MYPI2016704405A patent/MY192861A/en unknown
- 2015-05-27 TN TN2016000511A patent/TN2016000511A1/en unknown
- 2015-05-27 HR HRP20181490TT patent/HRP20181490T1/hr unknown
- 2015-05-27 AP AP2016009578A patent/AP2016009578A0/en unknown
- 2015-05-27 LT LTEP15726266.8T patent/LT3148994T/lt unknown
- 2015-05-27 BR BR112016028002-4A patent/BR112016028002B1/pt active IP Right Grant
- 2015-05-27 SI SI201530403T patent/SI3148994T1/sl unknown
- 2015-05-27 ES ES15726266.8T patent/ES2688396T3/es active Active
- 2015-05-27 HU HUE15726266A patent/HUE039879T2/hu unknown
- 2015-05-27 PT PT15726266T patent/PT3148994T/pt unknown
- 2015-05-27 EA EA201692260A patent/EA030937B1/ru not_active IP Right Cessation
- 2015-05-27 WO PCT/GB2015/051537 patent/WO2015181539A1/en not_active Ceased
- 2015-05-27 KR KR1020167036577A patent/KR20170005875A/ko not_active Abandoned
- 2015-05-27 AU AU2015265703A patent/AU2015265703B2/en active Active
- 2015-05-27 PL PL15726266T patent/PL3148994T3/pl unknown
- 2015-05-27 JP JP2017514983A patent/JP6538830B2/ja active Active
- 2015-05-27 DK DK15726266.8T patent/DK3148994T3/en active
- 2015-05-27 RS RS20181101A patent/RS57876B1/sr unknown
- 2015-05-27 NZ NZ726790A patent/NZ726790A/en not_active IP Right Cessation
- 2015-05-27 US US15/314,562 patent/US10040788B2/en active Active
- 2015-05-27 CA CA2949598A patent/CA2949598C/en active Active
- 2015-05-27 MX MX2016015738A patent/MX2016015738A/es unknown
- 2015-05-27 SG SG11201609880QA patent/SG11201609880QA/en unknown
- 2015-05-27 EP EP15726266.8A patent/EP3148994B1/en active Active
- 2015-05-27 SM SM20180516T patent/SMT201800516T1/it unknown
- 2015-05-27 CN CN201580041233.9A patent/CN106795150B/zh active Active
- 2015-05-27 CR CR20160558A patent/CR20160558A/es unknown
- 2015-05-28 UY UY0001036145A patent/UY36145A/es not_active Application Discontinuation
- 2015-05-29 TW TW104117531A patent/TWI693220B/zh not_active IP Right Cessation
- 2015-05-29 AR ARP150101720A patent/AR100694A1/es unknown
-
2016
- 2016-11-17 IL IL249020A patent/IL249020B/en active IP Right Grant
- 2016-11-23 DO DO2016000308A patent/DOP2016000308A/es unknown
- 2016-11-28 GT GT201600250A patent/GT201600250A/es unknown
- 2016-11-29 CL CL2016003074A patent/CL2016003074A1/es unknown
- 2016-11-30 SV SV2016005330A patent/SV2016005330A/es unknown
- 2016-11-30 NI NI201600176A patent/NI201600176A/es unknown
- 2016-12-01 PH PH12016502394A patent/PH12016502394A1/en unknown
-
2018
- 2018-07-02 US US16/025,455 patent/US10294221B2/en active Active
- 2018-09-20 CY CY181100975T patent/CY1120836T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170148A1 (es) | Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer | |
| CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
| MA32727B1 (fr) | Pyrazolylaminopyridines au titre d'inhibiteurs de fak | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| CL2009000483A1 (es) | Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer. | |
| CL2017001426A1 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales. | |
| EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
| CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
| CL2011000191A1 (es) | Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
| CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
| CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
| EA201590748A1 (ru) | Противовирусные соединения против rsv | |
| CY1120619T1 (el) | Χημικες οντοτητες | |
| EA201390609A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
| CL2008002131A1 (es) | Compuestos heterociclos de amidas derivados de pirimidinas sustituidas por heterociclos y heterobiciclicos, inhibidores de la proteincinasa; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades proliferativas, neurologicas o neurodegenerativas, cardiovasculares, virosica o fungicas. | |
| EA201170252A1 (ru) | Амидофеноксиндазолы в качестве ингибиторов c-мет | |
| CL2008002097A1 (es) | Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| CL2012002250A1 (es) | Compuestos heterociclicos fusionados derivados de pirimidinonas, inhibidores potentes de cdc7; composicion farmaceutica; y su uso en la prevencion o el tratamiento del cancer. | |
| ECSP12011799A (es) | Compuestos de espiropiperidina y uso farmacéutico de los mismos | |
| CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
| EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
| BR112016015236A2 (pt) | inibidores de serina/treonina quinase | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina |